Stemline Therapeutics reported U$29230 in Cash and Equivalent for its first quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Abbvie U$ 6017M 35125M
Agenus U$ 79.171M 13.113M
Amgen U$ 9145M 1458M
Biocryst Pharmaceuticals U$ 173M 72M
Bristol Myers Squibb U$ 19934M 4117M
Celldex Therapeutics U$ 68M 46M
Daiichi Sankyo Y 382102M 42082M
Eisai Y 226308M 27936M
Geron U$ 22M 2M
GlaxoSmithKline 8166M 3397M
Halozyme Therapeutics U$ 133.606M 28.786M
Immunogen U$ 219.506M 27.793M
Merk U$ 11103M 3678M
Pfizer U$ 1801M 350M
Seattle Genetics U$ 117.32M 131.796M
Stemline Therapeutics U$ 29M 16M
Sumitomo Dainippon Y 113378M 11670M
United Therapeutics U$ 685.4M 189.8M
Verastem U$ 125M 10M